AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01116817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumbar puncture (Lopinavir/ritonavir monotherapy)
Description: Lumbar puncture at week 0
Study NCT03467971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin/Gliclazide Fixed Combination
Description: Participants will receive single oral dose of Metformin 1000 mg and Gliclazide 30 mg fixed combination tablet in fasting or fed state.
Study NCT00481871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralatrexate Injection
Description: Intravenous (IV) push administration over 30 seconds to 5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).~Sequential Dosing: 10 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met.~Same Day Dosing: 15 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met.
Study NCT01116817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar puncture (HAART: Lopinavir/ritonavir + 2 NRTI)
Description: Lumbar puncture at week 0
Study NCT02652728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril Orodispersible Minitablet
Description: Weight-dependent dose titration and long-term treatment scheme with enalapril ODMTs of 0.25 mg and 1 mg strength
Study NCT00930111 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2-week rotation
Description: Attending physician is assigned to a 2-week rotation.
Study NCT00930111 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 4-week rotation
Description: Attending physician is assigned to a 4-week rotation.
Study NCT02649686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Study NCT02649686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Study NCT03073603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Discontinuation of disease modifying therapy
Description: Participants who will discontinue their current MS drug. No other changes to their treatment occur.
Study NCT03073603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Participants who remain on their current Disease Modifying Therapies (DMTs) without any changes. DMTs include \~14 formulations/doses of drugs approved in the US by the FDA that alter the natural history of the disease.
Study NCT01177111 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunflower seed oil
Description: Locally manufactured refined sunflower seed oil will be provided to pregnant women late in pregnancy and community workers will promote its daily use during massage of newborns during the first month of life
Study NCT01177111 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mustard seed oil
Description: Locally manufactured mustard seed oil will be provided to pregnant women late in pregnancy and community workers will promote its daily use during massage of newborns during the first month of life
Study NCT01391104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Sildenafil citrate is a phosphodiesterase type-5 inhibitor. Patients will be assigned to sildenafil (20 mg tid) or placebo per os for 28 days in a randomized, double-blind manner. After a four-week wash-out period, patients will then be crossed over to the alternate therapy for the next 28 days.
Study NCT01391104 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: Patients will be assigned to sildenafil (20 mg tid) or placebo per os for 28 days in a randomized, double-blind manner. After a four-week wash-out period, patients will then be crossed over to the alternate therapy for the next 28 days.
Study NCT01181934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A643 (nicotine)
Description: 2mg oromucosal nicotine spray- three times daily during each treatment period
Study NCT01181934 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo - three times daily during each treatment period
Study NCT00481871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Gemcitabine will be prepared and administered as an IV infusion as per manufacturer instructions.~Sequential Dosing: 400 mg/m2 every 2 weeks (days 2 and 16) of a 4-week cycle until criteria for discontinuation per the protocol are met.~Same Day Dosing: 600 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met.
Study NCT01181934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A643 (nicotine)
Description: 1mg oromucosal nicotine spray- three times daily during each treatment period
Study NCT00006172 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bright light box
Description: 60-min light therapy shortly after awakening
Study NCT00006172 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-output negative ion generator
Description: 60-min high-density ion exposure shortly after awakening
Study NCT00006172 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Low-output negative ion generator
Description: 60-min low-density ion exposure shortly after awakening
Study NCT01480700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional study
Description: subjects consume 2 eggs per day during 4 months
Study NCT01480700 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional study
Description: subjects consume 2 eggs per day during 4 months
Study NCT00455195 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alglucosidase alfa
Description: IV infusion of 20 mg/kg; every other week (qow)
Study NCT04434404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Carnitine 500Mg Oral Tablet
Description: eighty-three eligible patients were recruited 33, 25, and 25 patients in the control group, L-carnitine group, and, Silymarin group respectively, completed the study~without cardioprotective agents in a dose of 50 mg/m2. L-carnitine group received anthracycline-containing chemotherapy in a dose of 50 mg/m2 plus L-carnitine 3 gm L-carnitine® capsules obtained from (MEPACO) was taken PO one day before chemotherapeutic cycle and 1gm /day during the following 21 days. Silymarin group received anthracycline-containing chemotherapy in a dose of 50 mg/m2 plus Silymarin as cardioprotective agent.140 mg (Legalon ® 140 mg capsule obtained from (MEDA). Silymarin was taken PO once daily after meals during the chemotherapeutic cycle. The treatment period was 6 months.
Study NCT04434404 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: L-Carnitine 500Mg Oral Tablet
Description: eighty-three eligible patients were recruited 33, 25, and 25 patients in the control group, L-carnitine group, and, Silymarin group respectively, completed the study~without cardioprotective agents in a dose of 50 mg/m2. L-carnitine group received anthracycline-containing chemotherapy in a dose of 50 mg/m2 plus L-carnitine 3 gm L-carnitine® capsules obtained from (MEPACO) was taken PO one day before chemotherapeutic cycle and 1gm /day during the following 21 days. Silymarin group received anthracycline-containing chemotherapy in a dose of 50 mg/m2 plus Silymarin as cardioprotective agent.140 mg (Legalon ® 140 mg capsule obtained from (MEDA). Silymarin was taken PO once daily after meals during the chemotherapeutic cycle. The treatment period was 6 months.
Study NCT02250404 — intervention group
Intervention type: OTHER
Intervention: cytology specimen collection procedure
Description: Correlative studies
Study NCT02250404 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01019330 — intervention group
Intervention type: OTHER
Intervention: Allen's test
Description: The Allen's test checks to make sure that radial and ulnar arteries that supply blood to the hand are not blocked. A pulse oximeter is placed on the index finger of the hand. The subject is asked to make a fist for 10 seconds.At this time, pressure is applied over the ulnar and radial arteries as to occlude (block) both of them. The pulse oximeter reading will begin to fall. Radial arterial pressure is then released. If the artery is patent (working), the pulse oximeter reading will begin to rise.
Study NCT00481871 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: 1 mg intramuscular injection~Administered within 10 weeks of enrollment, every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate.
Study NCT00481871 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: 1 mg orally~Administered daily for at least 7 days prior to start of pralatrexate, throughout the study and for at least 30 days after last dose of pralatrexate.
Study NCT03084978 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia
Description: General anesthesia by standard endotracheal intubation.
Study NCT03084978 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conscious Sedation
Description: Conscious sedation
Study NCT01395693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Salt Lake mask system
Description: Study participants will Salt Lake mask system for 1 week in place of their current mask system.
Study NCT02522949 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ColdZyme® mouth spray
Study NCT02522949 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00769015 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BA-LVR
Description: Low vision clinic-based optometry plus 6 in-home occupational therapy visits
Study NCT00769015 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: ST-LVR
Description: Clinic-based low vision optometry plus 6 in-home sessions of Supportive Therapy
Study NCT02020655 — intervention group
Intervention type: OTHER
Intervention: Shear- force model
Description: Shear- force model
Study NCT05073263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Patient is randomized to the weightbearing group the day after surgery.
Study NCT05073263 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Patient is randomized to the weightbearing group the day after surgery.
Study NCT05224297 — intervention group
Intervention type: RADIATION
Intervention: external beam photon therapy
Description: Patients receive external beam photon therapy for different tumor locations (groups).
Study NCT01019330 — intervention group
Intervention type: OTHER
Intervention: Distal pulses
Description: Practitioner will check that the dorsalis pedis and posterior tibialis are palpable.
Study NCT01186523 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long Term Energy Balance
Description: To see if there is a variance in weight loss and energy balance between men and women with similar energy expenditure over an extended period of time.
Study NCT04475601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide Pill
Description: The once daily dose will be given only during hospitalization and stop if starting invasive mechanical ventilation or at discharge from hospital
Study NCT03377387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be taken orally in AM and PM (at the assigned dose per cohort) 7 days on and 7 days off. Phase II MD 1000mg BID of capecitabine.
Study NCT03377387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Neratinib is given as 240 mg daily continuously without stopping. A cycle is 28 days. Phase II The MD has been determined as 240mg of neratinib
Study NCT03377387 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EORTC QLQ - BR23, EQ-5D-5L, EORTC QLQ-C30
Description: Questionnaires Every Cycle (+/- 3 days) (For phase II)
Study NCT00509340 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: Participants in this group will receive individual sessions of cognitive-behavioral training for improvement of medication adherence and reduction of depression.
Study NCT01514409 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5-Hydroxytryptophan
Description: Thirty-three participants were randomly allocated in a double-blind manner to receive either 3x50mg capsules of 5-HTP or placebo (silica) for 14 days.~5-HTP is produced commercially by extraction from the seeds of the African plant griffonia simplicifolia.
Study NCT01514409 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Pharmaceutical grade silica
Description: Pharmaceutical grade silica was utilized as placebo
Study NCT03202186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone oral capsule
Description: Oral capsule treatment
Study NCT03202186 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Oral capsule treatment
Study NCT04434638 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transitions of Care Coordinator
Description: We developed the Transition of Care Coordinator (TOCC) program to aid in the completion of the diagnostic evaluations as well as in the transition out of the acute care hospital setting. In the TOCC intervention, the stroke nurse navigator completed eight specific tasks: (1) met the patient and family within 48 hours of admission, (2) identified patient home location and insurance status, (3) coordinated communication between treating providers (neurologists, cardiologists, etc.) regarding pending diagnostic tests, (4) followed up physical, occupational, and speech therapy teams' recommendations for rehabilitation, (5) attended daily multi-disciplinary rounds, (6) facilitated referrals to acute and subacute rehabilitation facilities with case managers, (7) assisted beside nurses in providing tailored stroke education and discharge instructions to patients and families, and (8) arranged stroke clinic follow-up appointments.
Study NCT04434638 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients received the current, ongoing method of care coordination by members of the multi-disciplinary stroke team. The current practice is that members of this multi-disciplinary team meet with each other every weekday morning to discuss the discharge plan of care for each stroke patient on the inpatient stroke service. Physicians, nurses, rehabilitation therapists and case managers are then individually responsible for talking to patients and their families/caregivers about the different aspects of the plan of care.
Study NCT01770678 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constraint Induced Movement Therapy
Description: A combination of prolonged restraint of the unaffected upper limb and massed practice of the affected upper limb.
Study NCT01770678 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Constraint Induced Movement Therapy
Description: A combination of prolonged restraint of the unaffected upper limb and massed practice of the affected upper limb.
Study NCT02756078 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TEST Contact Lens
Study NCT02756078 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CONTROL Contact Lens
Study NCT03839784 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Neurocognition Interventions
Description: EEG, Neurocognitive Battery Testing, and Immune Profiles
Study NCT01141049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: During week 1 the dosage will be increased 3 times. Days 1 and 2, participants will receive 400 mg of Gabapentin three times daily. During days 3 and 4 the dosage will be increased to 800 mg three times daily. On day 5 through 7, participants will receive a dose of 1200 mg three times daily, which will continue from week 2 through 8. During week 9 patients will be tapered off for the duration of the week.
Study NCT01141049 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, TID
Study NCT01257828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: riluzole
Description: 50mg BID orally for 14 days prior to surgery and 28 days after the surgery
Study NCT01257828 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo medication
Description: 50mg BID orally for 14 days prior to surgery and 28 days after the surgery
Study NCT02349009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C-82 Topical Gel, 1%
Description: active
Study NCT02349009 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: C-82 Topical Gel, Placebo
Description: placebo
Study NCT02523729 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Anke Malz
Description: non-alcoholic malt drink
Study NCT04167280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipratropium Metered Dose Inhaler
Description: MDI to deliver 20mcg per puff ipratropium bromide
Study NCT04167280 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo metered dose inhaler
Description: matched MDI to deliver inactive drug
Study NCT01651494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DAS181
Description: DAS181-F04 is a recombinant neuraminidase that is delivered onto the cell surface of the upper and central airway topically and locally through an inhaler as an encapsulated dry powder. DAS181-F04; 20 mg single-dose each day via oral inhalation for 3 days; 6 subjects
Study NCT01651494 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: White to off-white powder with Lactose Monohydrate and 5 % moisture; 20 mg single-dose each day via oral inhalation for 3 days; 3 subjects
Study NCT04276285 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic TAP
Description: Subcostal TAP block will be performed after surgery under laparoscopic guidance
Study NCT04276285 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US TAP
Description: Subcostal TAP block will be performed after surgery under US guidance
Study NCT01637259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: arm 1 nucleotide analogue reverse transcriptase inhibitors and boosted protease inhibitors
Description: NRTI + PI
Study NCT01637259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm 2 boosted protease inhibitors and maraviroc
Description: PI + maraviroc
Study NCT01637259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm 3 nucleotide analogue reverse transcriptase inhibitors and maraviroc
Description: NRTI + maraviroc
Study NCT00136734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Study NCT00136734 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT03174509 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positive pressure extubation
Description: Positive pressure ventilation without endotracheal aspiration/suction during extubation procedure.
Study NCT03174509 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional during extubation
Description: Spontaneous ventilation with endotracheal aspiration/suction during extubation procedure.
Study NCT00297206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valaciclovir
Description: Valaciclovir will be administered as an extemporaneously prepared suspension formulation. Valaciclovir oral suspension will be prepared by crushing marketed Valtrex Caplets 500 milligram (mg) and suspending the resultant powder in Suspension Structured Vehicle USNF with dose strength of 25 milligram per milliliter (mg/mL) or 50 mg/mL.
Study NCT03384420 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD34+ cells enriched with MNV-BLD
Description: Transplantation of autologous stem cell enriched with MNV-BLD (blood-derived mitochondria)
Study NCT01491282 — intervention group
Intervention type: OTHER
Intervention: Enabling and disabling VNS
Description: No intervention
Study NCT01241812 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lower limb muscle strengthening
Description: Participants in the exercise group will receive a lower limb strengthening program consisting of 6 exercises targeting the quadriceps, hamstrings, and hip abductor groups. They will perform these exercises at home 4 times per week (3 sets of 10 repetitions per exercise). Over the course of the intervention, each participant will consult with the physiotherapist a total of 5 times (once per week in weeks: 1,2,3,5, and 8) to ensure proper performance of exercises and safe progression of resistance.
Study NCT04408300 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ophthalmological exam
Description: Retinophotography, OCT-A (Optical Coherence Tomography- Angiography), OCT-B scan (Optical Coherence Tomography B Scan), Measurement of corrected visual acuity in ETDRS (Early Treatment Diabetic Retinopathy Study), Measurement of intraocular pressure, adaptive optics
Study NCT00350337 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pre-transfection F17
Description: Dengue tetravalent Vaccine F17 Pre transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection
Study NCT00350337 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Post-transfection F17
Description: Dengue tetravalent Vaccine F17 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose.